Tissue and Metabolic Characterization of Arrhythmogenic Cardiomyopathies by Hybrid PET-MRI Imaging, Impact of the Observed Profiles on the Phenotype and on the Evolution of Cardiomyopathy

Launched by NANTES UNIVERSITY HOSPITAL · Jul 4, 2022

Keywords

ClinConnect Summary

This clinical trial is exploring a new imaging technique called hybrid PET-MRI to better understand arrhythmogenic cardiomyopathies (AC), a condition that can lead to serious heart issues like sudden death. Researchers want to see how this advanced imaging can help identify inflammation in the heart muscle, which may play a role in how the disease shows up and progresses. By studying 80 patients with genetic forms of AC, the trial aims to gather important information about the heart’s tissue and metabolism, which could lead to better treatment options in the future.

To participate in the trial, you need to be at least 16 years old and have a specific type of arrhythmogenic cardiomyopathy that does not involve certain genetic mutations or autoimmune diseases. Those who join will undergo non-invasive imaging tests, and researchers will look at the results to see how they relate to the disease's characteristics and development. This study is significant because it could provide the first non-invasive way to assess the heart's condition in AC patients, potentially changing how this condition is diagnosed and treated.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Male and female over 16 years old
• Exclusion Criteria:
• • Patients and their relatives with left ventricular or biventricular AC and carrier of a pathogenic or likely pathogenic variant in one of the following genes : PKP2, DSG2, DSC2, JUP, DSP, DES, FLNC, PLN, LMNA, TMEM43, CDH2, BAG3, RYR2, RBM20 Consent form
• Exclusion Criteria :
• • Sarcoidosis or known or diagnosed autoimmune disease
• • History of myocardial infarction
• • Patient under guardianship, curatorship or safeguard of justice